11/19
08:15 am
coya
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Low
Report
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
11/11
08:09 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
11/7
09:51 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
11/6
08:00 am
coya
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
Medium
Report
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
11/1
08:18 am
coya
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer [Yahoo! Finance]
Medium
Report
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer [Yahoo! Finance]
11/1
08:15 am
coya
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
Medium
Report
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
10/30
09:25 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
10/29
06:30 am
coya
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
High
Report
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
10/28
08:00 am
coya
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
High
Report
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
10/23
04:05 pm
coya
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
Low
Report
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
10/22
09:11 am
coya
Coya Therapeutics looks to raise $10M in private placement [Seeking Alpha]
High
Report
Coya Therapeutics looks to raise $10M in private placement [Seeking Alpha]
10/22
09:00 am
coya
Coya Therapeutics Announces $10.0 Million Private Placement
High
Report
Coya Therapeutics Announces $10.0 Million Private Placement
10/8
09:15 am
coya
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
Low
Report
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
9/24
08:20 am
coya
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference [Yahoo! Finance]
Medium
Report
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference [Yahoo! Finance]
9/24
08:15 am
coya
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
Medium
Report
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
9/16
08:15 am
coya
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
Medium
Report
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
9/16
08:03 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
9/3
08:22 am
coya
Coya Therapeutics to Present at Upcoming Healthcare Conferences [Yahoo! Finance]
Low
Report
Coya Therapeutics to Present at Upcoming Healthcare Conferences [Yahoo! Finance]
9/3
08:15 am
coya
Coya Therapeutics to Present at Upcoming Healthcare Conferences
Low
Report
Coya Therapeutics to Present at Upcoming Healthcare Conferences